An FDA peptide compounding policy is under OMB review, its text not public

ON THIS PAGE

1. Key findings
2. What the OIRA listing says
3. A meeting is already on the log
4. What OIRA review is
5. The FDA record closest to it: the July 2026 committee meeting
6. What stays unknown
7. Sources

A draft FDA policy on compounding with peptides is now at the White House. Its title is public. Its text is not.

The Office of Information and Regulatory Affairs (OIRA), part of the Office of Management and Budget, lists the action as pending review. That is the whole of the confirmed news. What the policy says, who it covers and when it might appear are all unknown, and anything claiming otherwise is ahead of the record.

What the OIRA listing says

The listing is short, and every field in it is quoted here. It sits in the EO 12866 regulatory review search on reginfo.gov, the government site run by the General Services Administration and OMB, read on October 18, 2026.

• Agency: HHS-FDA
• Title: Interim Access Policy for Compounding Using Certain Peptides
• RIN (Regulation Identifier Number): 0910-ZD94
• Status: Pending Review
• Stage: Notice
• Received date: 10/14/2026
• Economically significant: No
• Legal deadline: None

The detail page for the review, read the same day, adds four more No answers: international impacts, the Affordable Care Act, pandemic response, and the Dodd-Frank Act. It gives no abstract. The link to the RIN's Unified Agenda entry returned no description when read.

That blank has a plain cause. OIRA's FAQ on reginfo.gov, read October 18, 2026, says rule descriptions come from agencies' Unified Agenda filings. A blank entry means "the agency did not provide such descriptive information."

The economic flag also has a set meaning. Executive Order 12866 uses "economically significant" for an action likely to have an annual effect on the economy of $100 million or more, among other tests. The listing says No. It says nothing more about cost.

A meeting is already on the log

Outside groups can ask to meet OIRA about a rule under review. The EO 12866 meetings search on reginfo.gov, read October 18, 2026, returns one record for RIN 0910-ZD94: a meeting on October 21, 2026 at 3:00 p.m., listed as Scheduled, at the Notice stage. The record as displayed in the search results does not say who asked for it.

The executive order requires OIRA to keep a public log of such meetings, with dates, names and subject matter.

What OIRA review is

OIRA review is a check by the White House before an agency publishes certain actions. OIRA's FAQ says Executive Order 12866, signed September 30, 1993, "establishes and governs the process under which OIRA reviews agency draft and proposed final regulatory actions." Review covers actions found to be "significant."

The clock is set by the order. The FAQ says review is limited to 90 days, has no minimum, and can be extended once by the OMB Director for up to 30 days, or without limit by the agency head. The order's text, as posted on reginfo.gov and read October 18, 2026, sets a shorter limit of 10 working days for notices of inquiry and other early actions that come before a proposed rule. The listing does not say which limit applies here.

Review can end three ways. OIRA can conclude it. OIRA can return the draft with a written explanation, which its FAQ says "does not necessarily imply" opposition. Or the agency can withdraw it. Section 8 of the order bars the agency from publishing a reviewed action until review ends or the time runs out.

The stake for anyone reading coverage of this policy is simple. OIRA's FAQ says: "Draft documents under review are considered deliberative and are not available for public release during review." Any description of what the interim access policy allows or forbids is, for now, not drawn from the policy.

The FDA record closest to it: the July 2026 committee meeting

The listing does not mention any meeting, substance or prior FDA action. The nearest FDA record on the same subject is the Pharmacy Compounding Advisory Committee meeting of July 23 and 24, 2026. Nothing on the public record ties the two together beyond the topic.

FDA's meeting page, read October 18, 2026, says the committee would discuss substances "being considered for inclusion on the 503A Bulks List." That list names bulk drug substances that pharmacists may compound with under section 503A when no USP monograph or approved drug covers them, according to FDA's briefing introduction, read October 18, 2026.

Seven peptides were on the agenda, each in a free base and an acetate form:

• July 23: BPC-157, KPV, TB-500 and MOTS-c
• July 24: Emideltide (also called DSIP), Epitalon and Semax

The question sheet, read October 18, 2026, put one vote per form to the committee: "Should [the substance] be placed on the list?" That is 14 votes in all.

FDA's own position was stated in advance. The briefing introduction lists 14 points to consider, and each says FDA "is proposing" that the form "NOT be included on the 503A Bulks List." For BPC-157, the agency's briefing document, read October 18, 2026, concluded that "a balancing of the criteria weighs against" listing either form. It called BPC-157 free base "not well-characterized" from a chemistry standpoint, citing missing data on impurities, aggregates, bioburden and bacterial endotoxins.

One detail in the briefing introduction stands out. Every nomination for the seven peptides had been withdrawn by its nominator, and FDA's footnotes say the agency was "electing to proceed" with the presentations anyway.

FDA also said what the meeting would not do. The introduction says the agency "does not intend to issue a final determination" until the committee's input has been considered and all reviews are finalized. The fda.gov meeting page, read October 18, 2026, links the agenda, roster, questions, briefing documents and FDA slides. It linked no vote tally or minutes, and neither did the 2026 materials page.

What stays unknown

Most of what matters is not yet on any public page.

• The policy's text and scope are not public. OIRA does not release drafts under review.
• Which peptides "certain peptides" means is not stated in the listing.
• Whether the policy relates to the July committee meeting is not stated by any record read for this article.
• How the committee voted on the 14 questions was not posted on the fda.gov pages read.
• When the policy might be published is unknown. The listing gives no legal deadline.

Any outside account of the policy's contents runs into the same wall. The draft is not out.

Sources

1. reginfo.gov, EO 12866 regulatory review search, entry for RIN 0910-ZD94, and its review detail page. Read October 18, 2026.
2. reginfo.gov, EO 12866 meetings search results for RIN 0910-ZD94. Read October 18, 2026.
3. reginfo.gov, OIRA frequently asked questions. Read October 18, 2026.
4. Executive Order 12866, "Regulatory Planning and Review," 58 Fed. Reg. 51735 (October 4, 1993), as posted on reginfo.gov. Read October 18, 2026.
5. FDA, July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Read October 18, 2026.
6. FDA, FDA Briefing Document, PCAC Meeting July 23-24, 2026 (Introduction). Read October 18, 2026.
7. FDA, PCAC Meeting July 23-24, 2026, Questions. Read October 18, 2026.
8. FDA, FDA Briefing Document for BPC-157-Related Bulk Drug Substances. Read October 18, 2026.
9. FDA, 2026 Meeting Materials, Pharmacy Compounding Advisory Committee (fda.gov). Read October 18, 2026.

The draft's text becomes public when OIRA concludes its review or the agency publishes. Until then, the title is the story.